A New Platform for Making Longer-Lasting Therapeutic Peptides by Attaching Them to Albumin
Researchers developed a production platform that attaches therapeutic peptides to human serum albumin at precise locations, extending their time in the bloodstream — with GLP-1 as the proof-of-concept peptide.
Quick Facts
What This Study Found
The researchers successfully produced recombinant GLP-1 with a non-natural amino acid (p-azido-L-phenylalanine) incorporated at three specific positions (V16, Y19, and F28), then conjugated human serum albumin (HSA) at each site using click chemistry (strain-promoted azide-alkyne cycloaddition).
All three HSA-conjugated GLP-1 variants achieved comparable extended serum half-lives in vivo. However, their biological activities differed significantly: the variants showed different in vitro receptor activation and different glucose-lowering effects in vivo, demonstrating that the specific site of albumin attachment critically affects therapeutic function even when half-life extension is equivalent.
Key Numbers
How They Did This
The team used genetic code expansion to incorporate a clickable non-natural amino acid (AzF) at three specific positions in a GLP-1 variant produced in bacteria. They then conjugated HSA to each variant using strain-promoted azide-alkyne cycloaddition (a type of click chemistry that works under mild conditions). The conjugates were tested for in vitro biological activity (receptor activation assays) and in vivo performance including serum half-life and glucose-lowering effects in animal models.
Why This Research Matters
Peptide drugs are one of the fastest-growing segments of the pharmaceutical industry, but their short half-lives mean patients often need daily or even more frequent injections. This platform offers a generalizable solution: produce the peptide in bacteria (overcoming size limits of chemical synthesis) and attach albumin at the optimal site (extending duration without sacrificing activity). If the approach scales, it could accelerate the development of many long-acting peptide therapies beyond just GLP-1.
The Bigger Picture
Half-life extension is a central challenge in peptide drug development — it's why semaglutide works as a weekly injection while native GLP-1 lasts only minutes in the blood. Current strategies include fatty acid acylation (used in semaglutide), PEGylation, and albumin binding. This study adds site-specific albumin conjugation via genetic code expansion to the toolkit, offering potentially more precise control over where and how the carrier protein attaches. The finding that conjugation site dramatically affects activity, even when half-life is unchanged, is an important insight for the entire field of peptide engineering.
What This Study Doesn't Tell Us
The study used GLP-1 as a single model peptide, so the platform's effectiveness for other therapeutic peptides remains to be demonstrated. Only three conjugation sites were tested. The in vivo studies were conducted in animal models, and translation to human pharmacokinetics is uncertain. The recombinant production yield and scalability for manufacturing were not fully characterized. Long-term stability and immunogenicity of the conjugates were not assessed.
Questions This Raises
- ?Can this albumin conjugation platform maintain therapeutic activity for peptides with different structures and mechanisms than GLP-1?
- ?How does site-specific HSA conjugation compare to fatty acid acylation (as in semaglutide) in terms of half-life, activity, and manufacturing cost?
- ?Could computational modeling predict the optimal conjugation site for a given peptide without needing to test every position experimentally?
Trust & Context
- Key Stat:
- Same half-life, different activity by conjugation site All three albumin attachment sites on GLP-1 produced equivalent duration in the blood, but their glucose-lowering effects differed significantly — showing that where you attach the carrier matters as much as whether you attach it
- Evidence Grade:
- This is a preclinical proof-of-concept study demonstrating a new drug development platform. The results are consistent and well-controlled within the experimental framework, but the work is limited to one model peptide, animal models, and has not been tested in humans.
- Study Age:
- Published in 2020, this study reflects current bioconjugation and genetic code expansion technology. The platform approach remains relevant as the peptide therapeutics field continues to grow rapidly.
- Original Title:
- Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.
- Published In:
- Pharmaceutics, 12(4) (2020)
- Authors:
- Bak, Mijeong, Park, Junyong, Min, Kiyoon, Cho, Jinhwan, Seong, Jihyoun, Hahn, Young S, Tae, Giyoong, Kwon, Inchan
- Database ID:
- RPEP-04648
Evidence Hierarchy
Frequently Asked Questions
Why do peptide drugs need half-life extension in the first place?
Natural peptides like GLP-1 are broken down by enzymes in the blood within minutes, which would require near-continuous infusion to maintain therapeutic levels. By attaching peptides to long-lived proteins like albumin (which stays in the blood for about 3 weeks), the peptide drug is protected from rapid degradation and can be given much less frequently — potentially weekly or even monthly.
What is click chemistry and why is it used here?
Click chemistry refers to chemical reactions that snap molecules together reliably and precisely, like clicking LEGO pieces. In this study, the researchers used a specific type (strain-promoted azide-alkyne cycloaddition) that works under gentle conditions and doesn't damage the delicate peptide or albumin proteins. It allows them to attach albumin at exactly the right spot on the peptide.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04648APA
Bak, Mijeong; Park, Junyong; Min, Kiyoon; Cho, Jinhwan; Seong, Jihyoun; Hahn, Young S; Tae, Giyoong; Kwon, Inchan. (2020). Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.. Pharmaceutics, 12(4). https://doi.org/10.3390/pharmaceutics12040364
MLA
Bak, Mijeong, et al. "Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.." Pharmaceutics, 2020. https://doi.org/10.3390/pharmaceutics12040364
RethinkPeptides
RethinkPeptides Research Database. "Recombinant Peptide Production Platform Coupled with Site-Sp..." RPEP-04648. Retrieved from https://rethinkpeptides.com/research/bak-2020-recombinant-peptide-production-platform
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.